Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

13.00 +0.04 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avalo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
From Avalo Therapeutics
Via GlobeNewswire
Wondering what's happening in today's pre-market session?
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Avalo Reports 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024
AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.